Epioxa ™ HD 0.239% / Epioxa ™ 0.177% (riboflavin 5’-phosphate ophthalmic solution) is now available for use in epithelium-on ...

The melanocortin 4 receptor agonist setmelanotide is now FDA approved for weight management in adults and children with ...

Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

A federal court blocks changes to the childhood immunization schedule by the recently appointed vaccine advisory committee; higher dose Wegovy injection gets green light; Cosentyx expanded to include ...

Scientists are making rapid progress toward a long-awaited goal that could help to reshape cancer care: mRNA cancer vaccines ...

Significantly lower risks for MACE, all-cause mortality, incident myocardial infarction, stroke seen for adults 50 years and older with ASCVD.

Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...

Retatrutide is an investigational once-weekly triple hormone (glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon) receptor agonist.

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

Clinical benefits of the talazoparib and enzalutamide combination extend to patients with both BRCA and non-BRCA homologous recombination repair gene alterations.

Enh3ance trial results indicate DTX301 reduces ammonia levels by 18% and supports dietary liberalization in patients with OTC deficiency.

From 2023, there was a decrease in use of metabolic and bariatric surgery, with stronger decline for sleeve gastrectomy.